Castrate resistant prostate cancer (CRPC) is an advanced stage of prostate cancer that fails to respond to androgen deprivation therapy. It is more aggressive and difficult to treat compared to localized prostate cancer. The mainstay of treatment for CRPC includes chemotherapy drugs such as docetaxel, abiraterone acetate, enzalutamide, and cabazitaxel. However, these drugs provide only minimal increase in survival and are often associated with adverse effects compromising quality of life. ... Read more

Castrate resistant prostate cancer (CRPC) is an advanced stage of prostate cancer that fails to respond to androgen deprivation therapy. It is more aggressive and difficult to treat compared to localized prostate cancer. The mainstay of treatment for CRPC includes chemotherapy drugs such as docetaxel, abiraterone acetate, enzalutamide, and cabazitaxel. However, these drugs provide only minimal increase in survival and are often associated with adverse effects compromising quality of life. ... Read more

Prostate cancer is one of the commonly diagnosed cancers in men worldwide, causing a significant burden in terms of mortality and treatment costs. Castrate resistant prostate cancer (CRPC) refers to prostate cancer that continues to grow even after the primary treatment of androgen deprivation therapy. Drugs used for treating CRPC help improve symptom control and survival rates by slowing the growth of cancer cells.

The global Castrate Resistant Prostate Cancer ... Read more

The castrate resistant prostate cancer market primarily comprises pharmaceutical drugs treating advanced stages of prostate cancer. These drugs offer palliative treatment for patients who have developed resistance against standard hormone therapies like surgical or chemical castration. Some of the common drug classes in this market include cytochrome P-450 17 inhibitor, androgen receptor antagonist, taxanes and several others. Rising prevalence of prostate cancer especially in developed ... Read more